Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...
SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...
OCALA, Fla., March 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its participation in the Virtual Investor “ Top 5 for ‘25” On-Demand ...
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...
Compugen's pipeline, including COM701 and COM503, aims to transform tumor responsiveness through unique immunotherapy strategies, potentially reshaping the immuno-oncology landscape. Despite ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement ...
EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Establishing Strategic Presence in Europe With Initial Footprint in the UK 12.03.2025 / 14:06 CET/CEST The issuer is solely responsible for ...
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...
Recent data presented at leading international conferences (ASCO, ESMO, ASCO GI, AACR IO) and featured in prestigious journals (Nature Medicine, Journal of Clinical Oncology, Cancer Discovery), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback